Evidence map›Paper›PMID 28133901›Full record

ArticleDepression and anxiety2017

Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year.

Aimee R Kroll-Desrosiers, Benjamin C Nephew, Jessica A Babb, Yurima Guilarte-Walker, Tiffany A Moore Simas, Kristina M Deligiannidis

Open access · greenAbstract read
In one paragraph

Article in Depression and anxiety, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Oxytocin in Women's Health and Disease.Frontiers in endocrinology · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Neurobiology of peripartum mental illness.Handbook of clinical neurology · 2021
    Review
  18. Is Oxytocin "Nature's Medicine"?Pharmacological reviews · 2020
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aimee R Kroll-DesrosiersDepartment of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA.
Benjamin C NephewDepartment of Biomedical Sciences, Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, USA.
Jessica A BabbDepartment of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.
Yurima Guilarte-WalkerDepartment of Information Technology - Research Computing, University of Massachusetts Medical School, Worcester, MA, USA.
Tiffany A Moore SimasDepartments of Obstetrics & Gynecology, Pediatrics, and Psychiatry, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, USA.
Kristina M DeligiannidisWomen's Mental Health Program, Departments of Psychiatry and Obstetrics and Gynecology, University of Massachusetts Medical School, Worcester, MA, USA.
University of Massachusetts Chan Medical School · USBoston Children's Hospital · USTufts University · US

Funding

University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
University of Massachusetts Center for Clinical and Translational ScienceUL1TR000161 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2012 to 2015
$11.0M
Rapid Access to Perinatal Psychiatric Care in Depression Program (RAPPID): An Innovative Stepped-Care Approach for Obstetrics and Gynecology ClinicsU01DP006093 · DP · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BYATT, NANCY, MOORE SIMAS, TIFFANY ANNE · 2015 to 2019
$2.6M
Neuroendocrine and Neuroimaging Endophenotypes in Postpartum DepressionK23MH097794 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DELIGIANNIDIS, KRISTINA MARIE · 2013 to 2017
$897k
Vasopressin and Maternal BehaviorR00HD059943 · NICHD · TUFTS UNIVERSITY BOSTON · PI NEPHEW, BENJAMIN C · 2012 to 2014
$722k
Central Vasopressin and Maternal BehaviorK99HD059943 · NICHD · TUFTS UNIVERSITY BOSTON · PI NEPHEW, BENJAMIN C · 2009 to 2010
$201k
Serotonin, hippocampal theta, and copingF32MH108247 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI BABB, JESSICA A · 2015 to 2017
$182k
ACL HHS U01DP006093NCATS NIH HHS UL1 TR000161NCATS NIH HHS UL1 TR001453NCCDPHP CDC HHS U01 DP006093NICHD NIH HHS K99 HD059943NICHD NIH HHS R00 HD059943NIMH NIH HHS F32 MH108247NIMH NIH HHS K23 MH097794NIMH NIH HHS L30 MH104713
6 · The paper itself

Abstract

backgroundDue to its potent effects on social behavior, including maternal behavior, oxytocin has been identified as a potential mediator of postpartum depression and anxiety. The objective of this study was to examine the relationship between peripartum synthetic oxytocin administration and the development of depressive and anxiety disorders within the first year postpartum. We hypothesized that women exposed to peripartum synthetic oxytocin would have a reduced risk of postpartum depressive and anxiety disorders compared with those without any exposure.

methodsPopulation-based data available through the Massachusetts Integrated Clinical Academic Research Database (MiCARD) were used to retrospectively (2005-2014) examine this relationship and calculate the relative risk of peripartum synthetic oxytocin for the development of postpartum depressive and anxiety disorders in exposed (n = 9,684) compared to unexposed (n = 37,048) deliveries.

resultsAmong deliveries to women with a history of prepregnancy depressive or anxiety disorder, exposure to peripartum oxytocin increased the risk of postpartum depressive or anxiety disorder by 36% (relative risk (RR): 1.36; 95% confidence interval (95% CI): 1.20-1.55). In deliveries to women with no history of prepregnancy depressive or anxiety disorder, exposure to peripartum oxytocin increased the risk of postpartum depressive or anxiety disorder by 32% compared to those not exposed (RR: 1.32; 95% CI: 1.23-1.42).

conclusionsContrary to our hypothesis, results indicate that women with peripartum exposure to synthetic oxytocin had a higher relative risk of receiving a documented depressive or anxiety disorder diagnosis or antidepressant/anxiolytic prescription within the first year postpartum than women without synthetic oxytocin exposure.

Indexed as

Peripartum PeriodAdolescentAdultAnxiety DisordersDepression, PostpartumFemaleHumansMiddle AgedOxytocicsOxytocinPregnancyTreatment OutcomeYoung AdultOxytocicsOxytocinanxiety/anxiety disordersbiological markersdepressionmaternal-childpregnancy and postpartum

Identifiers

PMID28133901
PMCPMC5310833
OpenAlexW2582562037

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.